PBYI vs REGN: Which Stock is Better?
Side-by-side comparison of Puma Biotechnology Inc and Regeneron Pharmaceuticals Inc in 2026
PBYI
Puma Biotechnology Inc
—
REGN
Regeneron Pharmaceuticals Inc
$649.81
Key Metrics Comparison
| Metric | PBYI | REGN | Winner |
|---|---|---|---|
| Market Cap | $165.29M | $59.10B | REGN |
| P/E Ratio | 4.27 | 13.91 | PBYI |
| EPS (TTM) | $N/A | $N/A | Tie |
| Revenue Growth | 0.0% | 0.0% | Tie |
| Gross Margin | 0.0% | 0.0% | Tie |
Analyze PBYI
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is PBYI or REGN a better investment?
Comparing PBYI and REGN: Puma Biotechnology Inc has a market cap of $165.29M while Regeneron Pharmaceuticals Inc has $59.10B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between PBYI and REGN?
PBYI (Puma Biotechnology Inc) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: PBYI or REGN?
Based on P/E ratios, PBYI trades at a lower multiple (4.3x vs 13.9x).
Which is growing faster: PBYI or REGN?
Both PBYI and REGN show similar growth rates. Check our detailed analysis for quarterly trends.
Which company is more profitable: PBYI or REGN?
Both companies show comparable profitability metrics. View the full comparison above for detailed analysis.
Which is the larger company: PBYI or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $59.10B compared to $165.29M for PBYI.
Should I buy PBYI or REGN in 2026?
Both PBYI and REGN have investment merit. PBYI trades at $N/A while REGN trades at $649.81. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between PBYI and REGN stock?
Key differences: Market Cap ($165.29M vs $59.10B), P/E Ratio (4.3x vs 13.9x), Revenue Growth (0.0% vs 0.0%), Gross Margin (0.0% vs 0.0%).
Should I buy PBYI or REGN in 2026?
The choice between PBYI and REGN depends on your investment goals. REGN shows higher revenue growth (0.0%). REGN has better margins (0.0%). Consider your risk tolerance and time horizon.
What is the market cap comparison between PBYI and REGN?
PBYI (Puma Biotechnology Inc) has a market cap of $165.29M, while REGN (Regeneron Pharmaceuticals Inc) has a market cap of $59.10B. REGN is the larger company by market value.